Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?

Axsome Therapeutics' stock is expected to perform well in the next decade, driven by the expansion of its drug Auvelity into the Alzheimer's market. The company's focus on central nervous system disorders could lead to significant growth.